Year in Review 2024 - Transformative FDA Approvals in Precision Onco…

Oncology 2024 Year in Review

V. Subbiah

WCLC 2024 Insights: Optimal Management of Malignant Pleural Effusion

Insights from 2024 WCLC

P. Lee

ESMO 2024 Insights: Treatment Rechallenge After Grade 1 Trastuzumab-…

2024 ESMO Annual Meeting Insights Hub

K. Natsuhara

EGFRm Lung Cancer: Overview & Treatment Sequence

GRACE

J. Rotow

ESMO 2024 Summary: Key Trial Insights on Managing NSCLC With Low PD-…

ecancer

L. Paz-Ares

The Use of IO Doublet in PD-L1-Negative NSCLC

David Carbone

Imaging of Precision Therapy in Lung Cancer

International Cancer Imaging Society (ICIS)

M. Nishino

FDA Approval of Zenocutuzumab for Advanced NRG1 Fusion-Positive NSCL…

Memorial Sloan Kettering Cancer Center

A. Schram

Lazertinib in 1L EGFR-Mutant NSCLC: Unique Mechanism and Benefits of…

Mariam Alexander

An Update of ADC Toxicities in Solid Tumors

OncoAlert

M. Lustberg

Metastatic EGFRm NSCLC: 1L Therapy Options

University of Colorado Cancer Center

T. Patil

Surveillance Imaging in Solid Tumors: More Complicated Than It Appea…

ecancer

C. Booth

Evolution of 1L EGFR TKI Therapy in mNSCLC

Fawzi Abu Rous

Reading a Molecular Testing Report in Lung Cancer

GRACE

K. Yun

Year in Review 2024 - Targeted Therapy for NSCLC

Nebraska Oncology Society

J. Murray

Unresectable Stage 3 NSCLC: Patient Selection and Treatment Options

Fox Chase Cancer Center

C. Aggarwal

WCLC 2024 Review: MARIPOSA Trial - Extended Follow Up and Patient Re…

ecancer

E. Felip

Managing Cutaneous Toxicities in EGFRm NSCLC: Insights From Amivanta…

Catherine Shu

ALK, ROS1, and RET in NSCLC: Pushing the Boundaries of Targeted Ther…

GRACE

C. Bestvina

EGFR and HER2 Targeted Therapies in NSCLC: New Developments and a Ch…

GRACE

X. Le